brryh, the co-operation between Lilly and Lycia is to develop new antibodies and small molecules. Alterity has some 150 new and even patented molecules. So IMO at the moment, Alterity needs to do preclinical studies on which of these 150 molecules may have clinical value. The most important study is the ATH434 phase 2 study in the Multiple system atrophy population, which starts perhaps less than in 4 months. Perhaps the second most important study is the ATH434 study supported by the Michail Fox foundation in a primate model of Parkinson's disease.
IMO the most important possible co-operation issue of Alterity is a deal with PBT2. I do hope we get some new info about this in the preliminary annual report within the next few days as we usually get at the end of August.
ATH Price at posting:
3.4¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)